Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone
- 219 Downloads
To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC).
The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment.
AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p = 0.001).
AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.
KeywordsAnti-Mullerian hormone (AMH) Letrozole Breast cancer Fertility preservation Cryopreservation
This study is partially supported by NIH HD 053112.
- 6.American Cancer Society: Breast Cancer Facts & Figures 2005–2006. http://www.cancer.org/downloads/STT/CAFF2005BrFacspdf2005.pdf
- 19.Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. Prospective, comparative analysis of anti-mullerian hormone, inhibin B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010;93(3):855–64.PubMedCrossRefGoogle Scholar
- 23.Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–9.PubMedCrossRefGoogle Scholar
- 25.Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, et al. Correlations between anti-Mullerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. Eur J Med Res. 2007;12:604–8.PubMedGoogle Scholar
- 27.Guerif F, Lemseffer M, Couet ML, Gervereau O, Ract V, Royere D. Serum antimullerian hormone is not predictive of oocytes quality in vitro fertilization. Ann Endocrinol (Paris). 2009;70(4):230–4.Google Scholar